Delcath Systems, Inc. Announces Additional $35 Million in Funding Tied to the FDA Approval of HEPZATO KIT™

NEW YORK, Sept. 1, 2023 /PRNewswire/ -- Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that it...

Related Keywords

United States ,United Kingdom ,Ben Shamsian ,Gerard Michel ,Exchange Commission ,Prnewswire Delcath Systems Inc ,Access Program ,Nasdaq ,Venture Opportunities Fund ,Delcath Systems Inc ,Drug Administration ,Public Equity ,Hepatic Delivery System ,Avenue Venture Opportunities Fund ,Chief Executive ,Expanded Access Program ,Percutaneous Hepatic Perfusion ,Prescribing Information ,Risk Evaluation ,Mitigation Strategy ,Delcath Systems ,Delivery System ,Important Safety Information ,Boxed Warning ,Private Securities Litigation Reform Act ,Relations Contact ,